We also detected concomitant suppression of p65 rather than p52 during sunitinib treatment, and thus the canonical NF-κB pathway status should be considered in the clinical prediction of the therapeutic response of patients with ccRCC. Here, NFKB2 is linked to nonpapillary renal cell carcinoma.